Intellipharmaceutics International Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPCIF research report →
Price Chart
About the company
Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms. The company's U.
- CEO
- Isa Odidi MBA,
- IPO
- 2009
- Employees
- 11
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on IPCIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.96M
- P/E
- -1.72
- PEG
- 0.02
- P/S
- 75.52
- P/B
- -0.47
- EV/EBITDA
- -2.73
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -4336.82%
- Net Margin
- -4400.55%
- ROE
- 27.35%
- ROIC
- 34.55%
Latest fiscal year · YoY change
- Revenue
- $65.73K+0.0%
- Gross Profit
- $65.73K+134.5%
- Op Income
- $-2,850,507
- Net Income
- $-2,892,394+0.0%
- EPS
- $-0.09+11.1%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.15
- 52W Low
- $0.15
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.40
- RSI (14)
- 57
- Avg Volume
- 0
No earnings-call transcripts are available for IPCIF yet.
- Free Float
- 98.2%
- Shares Outstanding
- 33.09M
- Float Shares
- 32.51M
of shares held by institutions
7 13F filers
Our IPCIF coverage
Recent articles, reports, and earnings notes.
No research on IPCIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPCIF report →Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF)
defenseworld.net · Apr 15
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
defenseworld.net · Feb 1
Intellipharmaceutics Announces Downgrade to OTC Expert Market
accesswire.com · Jun 14
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
accesswire.com · Mar 13
Intellipharmaceutics Announces Cease Trade Order
accesswire.com · Mar 6
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
accesswire.com · Feb 26
Intellipharmaceutics International Inc. Announces Stock Option Grant
accesswire.com · Feb 8
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
accesswire.com · Jan 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.